Logo image of BBLG

BONE BIOLOGICS CORP (BBLG) Stock Fundamental Analysis

USA - NASDAQ:BBLG - US0980706008 - Common Stock

1.91 USD
-0.1 (-4.98%)
Last: 11/6/2025, 8:00:01 PM
Fundamental Rating

2

Taking everything into account, BBLG scores 2 out of 10 in our fundamental rating. BBLG was compared to 534 industry peers in the Biotechnology industry. While BBLG has a great health rating, there are worries on its profitability. BBLG does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year BBLG has reported negative net income.
BBLG had a negative operating cash flow in the past year.
BBLG had negative earnings in each of the past 5 years.
In the past 5 years BBLG always reported negative operating cash flow.
BBLG Yearly Net Income VS EBIT VS OCF VS FCFBBLG Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M -25M

1.2 Ratios

Looking at the Return On Assets, with a value of -106.15%, BBLG is doing worse than 76.78% of the companies in the same industry.
BBLG has a Return On Equity (-112.68%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -106.15%
ROE -112.68%
ROIC N/A
ROA(3y)-148.84%
ROA(5y)N/A
ROE(3y)-181.01%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BBLG Yearly ROA, ROE, ROICBBLG Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2K -2K -4K -6K -8K -10K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for BBLG so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BBLG Yearly Profit, Operating, Gross MarginsBBLG Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

7

2. Health

2.1 Basic Checks

The number of shares outstanding for BBLG has been increased compared to 1 year ago.
The number of shares outstanding for BBLG has been increased compared to 5 years ago.
There is no outstanding debt for BBLG. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
BBLG Yearly Shares OutstandingBBLG Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100K 200K 300K 400K
BBLG Yearly Total Debt VS Total AssetsBBLG Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

2.2 Solvency

BBLG has an Altman-Z score of -12.90. This is a bad value and indicates that BBLG is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of BBLG (-12.90) is worse than 77.53% of its industry peers.
There is no outstanding debt for BBLG. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -12.9
ROIC/WACCN/A
WACCN/A
BBLG Yearly LT Debt VS Equity VS FCFBBLG Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M 10M -10M

2.3 Liquidity

BBLG has a Current Ratio of 17.24. This indicates that BBLG is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 17.24, BBLG belongs to the top of the industry, outperforming 93.07% of the companies in the same industry.
BBLG has a Quick Ratio of 17.24. This indicates that BBLG is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 17.24, BBLG belongs to the best of the industry, outperforming 93.07% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 17.24
Quick Ratio 17.24
BBLG Yearly Current Assets VS Current LiabilitesBBLG Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 62.21% over the past year.
EPS 1Y (TTM)62.21%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%66.92%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, BBLG will show a very strong growth in Earnings Per Share. The EPS will grow by 36.50% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y86.23%
EPS Next 2Y36.5%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BBLG Yearly EPS VS EstimatesBBLG Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 -200 -400 -600 -800

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

BBLG reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BBLG. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BBLG Price Earnings VS Forward Price EarningsBBLG Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BBLG Per share dataBBLG EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10 -15 -20

4.3 Compensation for Growth

A more expensive valuation may be justified as BBLG's earnings are expected to grow with 36.50% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.5%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

BBLG does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BONE BIOLOGICS CORP

NASDAQ:BBLG (11/6/2025, 8:00:01 PM)

1.91

-0.1 (-4.98%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-14 2025-08-14/amc
Earnings (Next)11-12 2025-11-12/amc
Inst Owners0.12%
Inst Owner Change0%
Ins Owners0.04%
Ins Owner Change0%
Market Cap3.44M
Revenue(TTM)N/A
Net Income(TTM)-7432800
Analysts82.86
Price Target22.95 (1101.57%)
Short Float %3.32%
Short Ratio0.02
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-45.09%
Min EPS beat(2)-124.81%
Max EPS beat(2)34.64%
EPS beat(4)2
Avg EPS beat(4)-92.51%
Min EPS beat(4)-287.25%
Max EPS beat(4)34.64%
EPS beat(8)6
Avg EPS beat(8)-12.14%
EPS beat(12)9
Avg EPS beat(12)-17.29%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-132.07%
EPS NY rev (1m)0%
EPS NY rev (3m)-108.29%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.52
P/tB 0.52
EV/EBITDA N/A
EPS(TTM)-21.15
EYN/A
EPS(NY)-4.07
Fwd EYN/A
FCF(TTM)-1.84
FCFYN/A
OCF(TTM)-1.84
OCFYN/A
SpS0
BVpS3.66
TBVpS3.66
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -106.15%
ROE -112.68%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-148.84%
ROA(5y)N/A
ROE(3y)-181.01%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 17.24
Quick Ratio 17.24
Altman-Z -12.9
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)62.21%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%66.92%
EPS Next Y86.23%
EPS Next 2Y36.5%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y55.25%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y54.83%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y54.83%
OCF growth 3YN/A
OCF growth 5YN/A

BONE BIOLOGICS CORP / BBLG FAQ

Can you provide the ChartMill fundamental rating for BONE BIOLOGICS CORP?

ChartMill assigns a fundamental rating of 2 / 10 to BBLG.


What is the valuation status of BONE BIOLOGICS CORP (BBLG) stock?

ChartMill assigns a valuation rating of 1 / 10 to BONE BIOLOGICS CORP (BBLG). This can be considered as Overvalued.


What is the profitability of BBLG stock?

BONE BIOLOGICS CORP (BBLG) has a profitability rating of 0 / 10.


Can you provide the financial health for BBLG stock?

The financial health rating of BONE BIOLOGICS CORP (BBLG) is 7 / 10.